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1. Introduction
Bicuspid aortic valve (BAV) represents the most common cardiac congenital malformation
in the adult age, with strong male predominance. It may occur in isolation, or in association
with other congenital heart diseases. The BAV is seen in 1% to 2% of the population and
may be complicated by aortic stenosis or aortic insufficiency and infective endocarditis. It
may be associated with abnormalities of the aortic wall such as coarctation of the aorta, aort‐
ic dissection, and aortic aneurysm. Most patients with a BAV develop some complications
during life [1,2].
Congenital coronary anomalies, coronary atherosclerosis, and calcification have been descri‐
bed in association with BAV[3].
BAV has been identified at a prevalence of 4.6 cas-es per 1000 live births. The prevalence of
BAV according to sex has been found to be 7.1 cases per 1000 among male neonates, and 1.9
per 1000 among female neonates.
The congenitally BAV may function normally throughout life, may develop progressive cal‐
cification and stenosis or may develop regurgitation with or without infection. Aortic root
dilatation is common in BAV, even when the valve is haemodynamically normal, and conse‐
quently aortic dissection usually occurs in previously asymptomatic patients [4,5].
Aortic stenosis and regurgitation, infective endocarditis and aortic dissection are the most
common complications. Left coronary artery dominance is more common in patients with a
BAV (29-56.8%) and in 90% of cases, the left main coronary artery is less than 5 mm in
length [6-8]. The ignorance of these associations may cause an inadequate myocardial pres‐
ervation and an increased risk of myocardial infarction[9,10].
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Accordingly, associated congenital cardiovascular anomalies have been reported in as many
as 25% of patients. Patent ductus arteriosus and ventricular septal defect are the most fre‐
quent heart defects associated with BAVdisease [11].
1.1. Embryology and pathogenesis
The definitive fetal cardiac structure is evident from the second week of gestation, whereas
separation of the heart into four chambers is completed during the sixth and seventh weeks
of gestation resulting in separated systemic and pulmonary circulation[12]. The process of
aortic valve morphogenesis begins from the cardiac cushions located in the ventricular out‐
flow tract of the primary heart tube. In the outflow tract, the truncal cushion swellings con‐
tribute to form three leaflet valves of the aorta and pulmonary artery.The initial endocardial
cushions, which will contribute to all four cardiac valves, are formed by the thickening of
the extracellular matrix in the region of the atrioventricular and outflow tract.This process is
initiated by the secretion of extracellular matrix proteins such as fibronectin and transferrin
across the cardiac jelly to the adjacent endocardium. The endocardium then secretes trans‐
forming growth factor beta family members, which act synergistically with bone morphoge‐
netic protein-2 secreted by the myocardium, to increase mesenchyme formation and
proliferation, which results in the growth of the endothelial cushions. The myocardial cells
then invade the margins of the cellular endothelial cushions [13].
The semilunar valves form the division of the truncus arteriosus into two separate channels
which form the aortic and pulmonary trunks..The channels are created by the fusion of two
truncal ridges across the lumen. In each channel a third swelling occurs opposite the first
two which will form the 3rd leaflet. In the normal aortic valve the left and right leaflets of
the adult valve are formed from the respective swellings while the posterior leaflet is
formed from a swelling in the aortic trunk.
The pathogenesis of BAV is not yet fully understood. There is certainly a genetic compo‐
nent, especially given the association of BAV with other congenital abnormalities. However,
fusion of the right and left valve cushions at the beginning ofvalvulogenesis appears to be a
key factor in BAV formation [14].
A previous study suggested that BAV is a consequence of the anomalous behavior of cells
derived from the neural crest because BAV often is associated with congenital aortic arch
malformations and other neural crest-derived systems [15]. Other studies suggest that ex‐
tracellular matrix proteins may affect the initiation of cell differentiation during valvulogen‐
esis, while a molecular abnormality in this process may lead to the formation of abnormal
cusps [16,17]. Some researchers suggest that a molecular abnormality in the extracellular
matrix may lead to abnormal valvulogenesis, becouse matrix proteins help direct cell differ‐
entiation and cusp formation during valvulogenesis [16-18]. This could also explain why
BAVis often linked to other cardiovascular anomalies.
These abnormalities cause the fusion of two cusps and lead to one larger cusp; therefore, the
BAV usually includes two unequally sized cusps, the presence of a central raphe, and
smooth cusp margin. A previous studies showed that raphal position was between the right
and left cusp in 86% of cases [19]. An anomalous origin of coronary arteries depends on the
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spatial orientation of the two cusps. When the orientation of the cusps is anteroposterior, the
coronary arteries originate from the anterior sinus or if cusps laterlateral oriented the right
coronary artery originate from the common trunk and right Valsava’s sinus [20].
A recent study has demonstrated that BAVs with fused right and noncoronary leaflets and
those with fused right and left leaflets are different etiological entities. BAVs with fused
right and noncoronary leaflets result from a morphogenetic defect that occurs before cardiac
outflow tract septation on the basis of an exacerbated nitric oxide-dependent epithelialto-
mesenchymal transformation. On the other hand, BAVs with fused right and left leaflets re‐
sult from anomalous septation of the proximal portion of the cardiac outflow tract, caused
by dysfunctional neural crest cells [21].
The pulmonary valve can also be bicuspid, although this is much rarer and is most com‐
monly associated with congenital heart disease such as Tetralogy of Fallot. There have been
less than 10 cases reported in the literature of an isolated bicuspid pulmonary valve [22].
Deficient fibrillin-1 content in the vasculature of BAV patients may trigger matrix metallo‐
proteinase production, thereby leading to matrix disruption and dilation. It has been noted
that the fibrillin-1 content was remarkably reduced in the aorta of BAV patients, compared
with that of patients with a tricuspid aortic valve. Aortic elasticity measurements of BAV pa‐
tients suggest that diminished aortic elasticity is at least part of its causation [23-25].
1.2. Anatomy
The bicuspid valve is composed of two leaflets, of which one is usually larger (due to fusion of
two cusps leading to one larger cusp), and unequal cusp size the presence of a central raphe
(usually in the center of the larger of the two cusps). The raphe or fibrous ridge is the site of con‐
genital fusion of the two components of the conjoined cusps and does not contain valve tissue
(Figure 1) Three morphologies are identified: type 1, fusion of right coronary cusp and left cor‐
onary cusp; type 2, fusion of right coronary cusp and noncoronary cusp; and type 3, fusion of
left coronary cusp and noncoronary cusp. The most common is type 1 (70% to 85%), followed
by type 2 (10% to 30%) and most rare type 3 (1% ) [13,19,26] (Figure 2).
Figure 1. Transesophageal short-axis view of a BAV. There is fusion of the right and left cusps. The arrow points to the
raphe.
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Figure 2. The classification and incidence of BAVs.
The site of cusp fusion can have e฀ects on the prognosis of BAV [27], with the suggestion
that type 1 BAVs are more likely to stenose as adults while type 2 valves will have complica‐
tions at a younger age. The fused valve leaflet in BAV is actually smaller in area. Valvular
incompetence is usually caused by the redundancy of one cusp, since the two cusps usually
have different dimensions [28]
The coronary anatomy can be abnormal. Most patients with BAV disease have a left dominant
coronary circulation [29]. This left coronary can arise from the pulmonary artery. The left main
can also be up to 50% shorter than in normal in up to 90% of cases. This is an important consid‐
eration for any aortic valve surgery. The commonest abnormality associated with BAV is dila‐
tation of the thoracic aorta, also known as aortopathy. This is thought not only to be due to the
altered flow in the aorta, but also due to cellular structural abnormalities including decreased
fibrillin, causing smooth muscle cell detachment, and cell death [30].
The other abnormality found in conjunction with BAV disease is coarctation of the aorta.
[22,31]. The presence of coarctation and a poor result from repair can lead to more rapid fail‐
ure of the valve or aortic dissection.
1.3. Genetics
BAV is an inheritable disorder, with a family recurrence rate of approximately 35% [33]. Re‐
cent clinical studies have reported a 9% prevalence of BAV in first-degree relatives of pa‐
tients with BAV which was the estimated population prevalance of 1-2% [33-35].
BAV is likely due to mutations in different genes with dissimilar patterns of inheritance [33].
The first genetic cause of BAV is Anderson syndrome, which is reported to be a result of
mutations in the potassium channel gene KCNJ2 (chromosome 17q24.3)], whereas it clinical‐
ly presents as ventricular arrhythmias, periodic paralysis, and scoliosis [36]. Another muta‐
tions in a gene called NOTCH1(gene map locus 9q34.3), a transmembrane receptor that has
a role in determining cell outcome in organogenesis, were noted in two families with BAV
[37]. Regions 18q, 5q, and 13q are reported to contain genes responsible for BAV and/or as‐
sociated cardiovascular malformations [38,39]. The region 10q contains the ACTA2 gene,
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which encodes for smooth muscle alpha-actin (ACTA2), and mutation in this gene can result
in thoracic aneurysm and, in some instances, BAV [40]. Also the ubiquitin fusion degrada‐
tion 1–like gene UFD1L (chromosome 22q11.2) expressed in the outflow tract during em‐
bryogenesis is down-regulated in BAV tissue when compared with trileaflet valve tissue
[41]. The UFD1L gene encodesa component of a multi-enzyme complex involved in the deg‐
radation of ubiquitin fusion proteins, and is highly expressed during embryogenesis in cer‐
tain tissues. It seems to play a key role in the development of ectoderm-derived structures,
including neural crest cells.Downregulation of the UFD1L gene, hypothetically resulting
from an anomalous behavior of neural crest cells, may lead to reduced degradation activi‐
ties, and may finally lead to fusion of valve cushions, a key factor in the development of
congenital BAV[42]. Recent American College of Cardiology (ACC)/American Heart Associ‐
ation (AHA) adult congenital heart disease guidelines suggest echocardiographic screening
for BAV and aortopathy in first-degree relatives of patients with BAV [43,44].
Although these valves are more common in males than females by a factor of 2:1 in the gen‐
eral population, the prevalance was equal in males and females in families having more
than one affected individual [45,46].
2. Diagnosis
Clinical findings are usually limited to auscultation with most patients having an ejection
systolic murmur heard loudest at the apex [47]. The S1 usually is normal but sometimes may
be associated with ejection click. The S2 is soft, and when aortic stenosis is present, S2 occurs
simultaneously with P2. In aortic stenosis, an ejection systolic murmur is heard in the left
second intercostal space but may also be transmitted to the carotid arteries. If aortic incom‐
petence is present, a diastolic murmur of aortic regurgitation may be heard.
The electrocardiogram is usually normal; and ECG changes are not specific in patients with
BAV: left ventricular hypertrophy, atrial enlargement, and arrhythmias may be present.
The mainstay of diagnosis is echocardiography (transthoracic or transoesophageal) which
can provide a definitive diagnosis in the majority of patients [ 92% sensitivity and 96% spe‐
cificity) [48,49]. Transesophageal echocardiography (TEE) is also very important for evaluat‐
ing the aortic valve and thoracic aorta, whereas the sensitivity and specifity of multiplane
technique for assessing aortic valve morphology is high [13].
The parasternal short axis view allows for direct visualization of the valve cusps. In this
view the normal triangular opening shape is lost, becoming more “fish mouth-”like in ap‐
pearance, more similar to the mitral valve. This is especially pronounced in systole, as in di‐
astole the raphe can appear similar to a commissure of the third cusp. Differentiating severe
bicuspid aortic stenosis from severe other aortic stenosis can also be difficult. In order to es‐
tablish the diagnosis, the valve must be visualized in systole in the short-axis view. In the
long-axis view, the valve often has an eccentric closure line and there is doming of the leaf‐
lets. If there is uncertainty in diagnosis, a TEE can improve visualization of the leaflets [50].
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For BAV associated with stenosis, mean gradient and maximal flow velocity should be
measured, but when regurgitation is present, the effective regurgitant area and Doppler jet
size should be evaluated. For asymptomatic patients with aortic stenosis, echocardiography
is recommended for evaluating disease progression. In asymptomatic patients, TTE recom‐
mended: every year for severe aortic stenosis, ever 1-2 years for moderate aortic stenosis and
every 3-5 years for mild aortic stenosis [51].
In patients with poor acustic window, cardiac magnetic resonance (MRI) and multidetector
computed tomography are useful for measuring the aortic valve area and is an alternative
method to echocardiography in selected cases. MRI especially will enable views of the valve
to be obtained without interference from calcification. It also allows for excellent assessment
of the aorta. A recent study of 123 patients with confirmed BAV found that 10% of the pa‐
tients were misidentified as having a tricuspid valve using transthoracic echo and 28% had a
nondiagnostic study, in comparison to 4% being misidentified as having a tricuspid valve
by MRI and 2% having a non-diagnostic study [52].
The current guidelines suggest that cardiac magnetic resonance imaging or cardiac comput‐
ed tomography is reasonable in patients with BAVs when aortic root dilatation is detected
by echocardiography to further quantify severity of dilatation and involvement of theas‐
cending aorta (Clas IIa; Level of Evidence: B)[53].
3. Clinic
The clinical presentation of patients with BAV can vary from severe valve disease in infancy
to asymptomatic valve disease in old age. It may be associated with abnormalities of the
aortic wall such as coarctation of the aorta, aortic dissection, and aortic aneurysm. Most pa‐
tients with a BAV develop some complications during life [1,2].
Congenital coronary anomalies, coronary atherosclerosis, and calcification have been descri‐
bed in association with BAV[3].
The congenitally BAV may function normally throughout life, may develop progressive cal‐
cification and stenosis or may develop regurgitation with or without infection. Aortic root
dilatation is common in BAV, even when the valve is haemodynamically normal, and conse‐
quently aortic dissection usually occurs in previously asymptomatic patients [4,5].
Sudden death may occur as a result of obstruction of the left ventricular outflow tract by a
congenital BAV [54]. BAV are in most cases remain undetected until infection or calcification
supervenes [55].
Aortic stenosis and regurgitation, infective endocarditis and aortic dissection are the most
common complications. Left coronary artery dominance is more common in patients with a
BAV (29-56.8%) and in 90% of cases, the left main coronary artery is less than 5 mm in
length [7,8]. The ignorance of these associations may cause an inadequate myocardial pres‐
ervation and an increased risk of myocardial infarction[9,10].
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Symptoms associated with aortic stenosis are angina pectoris, syncope, and congestive heart
failure. The most common complication of aortic stenosis is congestive heart failure sympto‐
matically presented with dyspnea, which is a result of combined diastolic and systolic dys‐
function [56]. Angina pectoris occurs in patients with severe aortic stenosis and in those who
do not have coronary artery disease; it may be a result of ventricular hypertrophy.
Syncope is another common symptom in patients with BAV. Syncope reflects the cerebral
hypoperfusion caused by the inability to increase stroke volume during physical activity.
The clinical presentation in patients with BAV and presence of other cardiac congenital de‐
fects depends from structural complexity of the heart. In patients with interventricular sep‐
tal defects, the clinical presentation depends on the size of the defect area and the grade of
aortic stenosis. If the interventricular defect is small, the patient may be asymptomatic, but
when the interventricular defect is large, cardiac output will decrease and Eisenmenger syn‐
drome will develop.
Two large recent series reported that clinical course of unoperated patients with BAV de‐
pends on age, stenosis, and aortic incompetence. The severe aortic stenosis, and severe aortic
incompetence in older patients increases the risk of primary cardiac events including cardiac
death. Both these studies suggest that intervention on the basis of early symptoms or incipi‐
ent cardiac dysfunction may decreases the mortality of patients with BAV [57,58].
The natural history of BAV has been evaluated several cohort studies. It is known to be vari‐
able and of course somewhat dependent on associated abnormalities. It can range from se‐
vere aortic stenosis in childhood to asymptomatic disease until old age. There have indeed
been incidental findings of a minimally calcified BAV in patients in their 70s.More common‐
ly however [in around 75% of patients] there is progressive fibrocalcific stenosis of the valve
eventually requiring surgery. This usually leads to presentation in middle age only around
2% of children have clinically significant BAV disease [59].
The prevalence of fibrosis, cystic medial necrosis, elastic fragmentation, and inflammation
has been shown to be significantly higher in patients with fusion of the left coronary and
right coronary cusps. fusion of the left coronary and right coronary cusps was associated
with a larger aortic root diameter and a smaller aortic arch,than was fusion of the right coro‐
nary and non-coronary cusps. Another study demonstraed that fusion of the right coronary
and non-coronary cusps correlated with the more rapid growth of ascending aortic diameter
in the pediatric population [60-63].
There have been a couple of studies looking at long-term followup of patients with unoper‐
ated BAV. A cohort of 212 asymptomatic patients with BAV were found to have the same
20-year survival rate as the normal population but an increased frequency of cardiac events
including aortic valve surgery, ascending aorta surgery and any other cardiovascular sur‐
gery. Predictive factors for cardiovascular events were found to be age ≥50 years and valve
degeneration at diagnosis while baseline ascending aorta ≥40 mm independently predicted
surgery for aorta dilatation. Another study [64] 642 patients were followed up for a mean of
9 years, again with a 10-year survival rate similar to the normal population [96%]. One or
more primary cardiac events occurred in 25% including cardiac death in 3, intervention on
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aortic valve or ascending aorta in 22%, aortic dissection or aneurysm in 2%, and congestive
heart failure requiring hospital admission in 2%. Independent predictors of primary cardiac
events were age older than 30 years, moderate or severe aortic stenosis, and moderate or se‐
vere aortic regurgitation [50].
In the another study [61].the incidence of aortic dissection was found to be 1.5% in all pa‐
tients regardless of the progression of BAV; however this increased markedly in patients
aged 50 or older at baseline to 17.4% and even more in those found to have aneurysm for‐
mation at baseline to [44.9%]. 25-year rate for aortic surgery was 25% and there was a signif‐
icant burden of progression of disease to cause aortic dissection with 49 of the 384 patients
without baseline aneurysms developing them during followup [22].
Although the clinical presentation of patients with BAV can vary from severe valve disease
in infancy to asymptomatic valve or thoracic aortic disease in old age, symptomstypically
develop in adulthood. The clinical manifestations relate to the function of the aortic
valve,the aortopathy/dissection, and acquired complications such as endocarditis. However
in childhood, BAV disease is commonly asymptomatic [61]
Estimates of late cardiac events were approximately 25% at a mean age of 44 years in the
study from Toronto and 40% at a mean age of 52 years in the Olmsted County study [62,63].
In the Olmsted County series, 27% of adults with BAV and no significant valve disease at
baseline required cardiovascular surgery within 20 years of follow-up. Twenty-two percent
of the patients in the Toronto cohort required intervention within 9 years of follow-up. In
both studies, age was an important determinant of outcomes supporting the notion held by
many that eventually most patients with BAV would require some form of intervention.
3.1. Aortic stenosis
A common complication of BAV disease is aortic stenosis. BAV is recognized as a frequent
cause of aortic stenosis in adults. Aortic stenosis has been found in 72% of adults with BAV.
In 388 patients with severe aortic valve disease alone, BAVs were found in 45% of the pa‐
tients with aortic stenosis and 24% of the patients with aortic regurgitation. In 110 patients
with severe combined aortic and mitral valve disease, BAVs were found in only 12% [64].
Among the 600 patients analyzed, 213 (36%) had pure aortic stenosis, 265 (44%) had pure
aortic regurgitation and 122 (20%) had combined stenosis and regurgitation. BAVs repre‐
sented 18%, as the third most important cause of aortic disorder following degenerative and
rheumatic changes, followed by infective endocarditis (5%) [65].
The main symptoms are exertional dyspnea, syncope, and chest pain. These patients should
be evaluated and managed similarly to patients with tricuspid aortic valve stenosis.
In the Joint Study of the Natural History of Congenital Heart Defects, one-third of the chil‐
dren in the cohort had increases in catheterization gradients during the 4- to 8-year follow-
up period. In the follow-up study, children with baseline peak left ventricular to aortic
gradients >50 mm Hg were at risk for serious cardiac events at a rate of 1.2% per year. In
theUnited Kingdom cohort.20% of children with mild aortic stenosis at baselinehad mild
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disease after 30 years of follow-up. Age was the primary determinant of valvular disease
progression [50,66].
In adults, with BAV, stenosis occurs by similar methods to the process in patients with tri‐
cuspid aortic valves. It is felt to be due to calcification, endothelial dysfunction, inflamma‐
tion, lipoprotein deposition, and ossification of the aortic side of the valve leaflets. There has
been a suggestion that leaflet orientation may be a predictive factor in the rate of valve
stenosis. The folding and creasing of the valves and the turbulent flow are felt to contribute
to development of fibrosis and calcification [59].more rapid progression in aortic valve gra‐
dients occurred in patients with anteroposteriorly located cusps[60]. However, not all stud‐
ies have found this association, and the 2 large studies in adults have not identified leaflet
orientation as a risk factor for late adverse events. Olmsted County study identified a com‐
posite index of valve degeneration, which incorporated valve thickening, calcification, and
mobility, that was an independent predictor of long-term cardiac events in a population of
adults with no baseline valve dysfunction. The predictive role of both morphology and
function in adults with BAV parallels that observed in series examining older adults with
aortic stenosis mostly of acquired basis [50,62,63].
3.2. Aortic incompetence
Primary aortic regurgitation without infective endocarditis was uncommon, and 32% had an
apparently normally functioning aortic valve [67].
One cohort of 118 BAV patients found that of 70 patients without aortic stenosis, 28 (40%
had moderate to severe aortic regurgitation. The mechanisms of aortic incompetence in chil‐
dren are usually due to prolapsing cusps, myxoid degeneration, postvalve surgery and after
balloon valvuloplasty or endocarditis, while as the patients age dilatation of the ascending
aorta can lead to a functionally regurgitant valve[68,69]. With age, aortic incompetence may
also develop secondary to dilation of the ascending aorta. In the Olmstead study of asymp‐
tomatic adults, 47% had some degree of aortic incompetence at baseline; however, interven‐
tions for severe aortic incompetence were relatively uncommon, occurring in only 3% of the
cohort during follow-up. In the Toronto study 21% of the population had moderate or se‐
vere aortic incompetence at baseline; however, only 6% had an intervention for symptomat‐
ic aortic incompetence or progressive left ventricular dysfunction [62,63].
3.3. Aortopathy/aortic dissection
BAV patients tend to develop vascular abnormalities of the aorta, such as dilation, coarcta‐
tion and dissection. Aortic dilation in BAV patients is thought to be caused by intrinsic aort‐
ic disease that is characterized by cystic medial necrosis and disruption of the extracellular
matrix due to fibrillin deficiency. BAV is often associated with dilatation of the aortic root
and the ascending aorta. This is otherwise known as aortopathy. This can lead to aneurysm
and dissection. The dilatation has been reported during childhood, and it has also been sug‐
gested that increased aortic size at baseline is predictive for earlier dilatation and worse out‐
comes. Aortic size is larger generally in patients with BAV compared to those with normal
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valves. The most likely risk factor for progression is felt to be age. Aortic root size itself is
related to valve morphology and the presence of significant disease [22,6]; however, a recent
study did suggest that while most patients with BAV and ascending aortic aneurysm had
severe valve dysfunction, there was a small proportion of patients (5%) who did have aneur‐
ysm formation without any aortic valve dysfunction [50].
In the ascending aorta as well as the pulmonary trunk, the severity of cystic medial necrosis,
elastic fragmentation and changes in the smooth muscle cell orientation have been found to
be significantly more severe in patients with bicuspid valves than in those with tricuspid
valves.
Factors leading to aortic dissection four years after the Bentall operation have been considered
to be an impact of congenital BAV or proximal anastomosis of venous grafts, or both [70].
Studies have suggested that patients with BAV have an intrinsic defect in the aortic wall that
results in aortic disease, regardless of aortic valve function. BAV was associated with signifi‐
cantly less intimal change, and less fragmentation and loss of elastic tissue, compared with
patients with a tricuspid aortic valve. Type I and III collagens were significantly decreased
in dilated aortas of BAV patients, compared with controls, particularly at the convexity. Ex‐
pression of messenger RNA [ribonucleic acid] for collagens was lower than normal only in
the regurgitant subgroup. Fewer smooth muscle cells and greater severity of elastic fiber
fragmentation were observed at the convexity than at the concavity [71-73].
Among 119 cases of fatal dissecting aneurysm of the aorta, 11 cases of congenital BAV (9%)
were observed. Among the latter, three had coarctation of the aorta and one had Turner’s
syndrome without coarctation. In each case, cystic medial necrosis of the aorta was present.
Hypertension was either established or inferred from cardiac weight in 73% of the cases.
The high incidence among subjects with dissecting aneurysm suggested a causative relation‐
ship between BAV and aortic dissecting aneurysm [74].
Many theories have been postulated for the mechanism of BAV aortopathy. For a long time
there has been felt to be a genetic component; however there is increasing evidence for a
haemodynamic mechanism. It is felt that it is due to defects in the aortic media, such as elas‐
tin fragmentation, loss of smooth muscle cells, and an increase in collagen [6,22]. Systemic
features have also been noted in BAV patients which may predispose to aneurysm forma‐
tion including systemic endothelial dysfunction and higher plasma levels of matrix metallo‐
proteinases [75].
Pathological examination of surgical specimens from the aortic wall of patients with aortic
dissection associated with BAV showed cystic medial necrosis or mucoid degeneration [76].
Matrix metalloproteinases (endogenous enzymes that degrade matrix components) have
been implicated in atherosclerotic aortic aneurysm formation and appear to be elevated in
the aorta of patients with BAVs [77].
The histological findings of BAV are nonspecific, and had been described by several authors
in patients with Marfan syndrome [78-80]. The histopathological appearance of thoracic
aortic aneurysm in Marfan and BAV is similar, and includes evidence of vascular smooth
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muscle cell (VSMC) apoptosis and extracellular matrix degeneration in the absence of a sig‐
nificant inflammatory response [81].
Abnormalities in the ascending aorta of the patients with BAV, specifically premature medi‐
al layer VSMC apoptosis, have been described, explaining the higherthan-expected preva‐
lance of aortic dissection in these patients [82].
Also recently studies show less elastic tissue in the aortas of BAV patients [83,84].
In patient with BAV there are fibrillin, fibronectin, and tenascin abnormality. Additionally
Bonderman et al suggested that a primary role for VMSC apoptosis in the development of
aneurysm these patients [85].
The FBN1 gene encodes fibrillin-1, a large glycoprotein that is secreted from cells and depos‐
ited in the extracellular matrix in structures called microfibrils. Microfibrils are found at the
periphery of elastic fibers, including the elastic fibers in the medial layer of the ascending
aorta, and in tissues not associated with elastic fibers.
The histopathological appearance of thoracic aortic aneurysm in Marfan and BAV is similar,
and includes evidence of VSMC apoptosis and extracellular matrix degeneration in the ab‐
sence of a significant inflammatory response. Abnormalities in the ascending aorta of the
patients with BAV, specifically premature medial layer smooth muscle cell apoptosis, have
been described, explaining the higherthan-expected prevalance of aortic dissection in these
patients [82,83].
Aortic root dilation has been documented in childhood, suggesting that this process begins
early in life. Furthermore, children with BAV have greater increases in aortic dimensions
than do children with trileaflet valves. In both children and adults, progressive dilation of
the aorta is more common in patients with larger aortas at baseline. In BAV disease, the aort‐
ic annulus, sinus, and proximal ascending aorta are larger than those found in adults with
trileaflet valves [50].
In the Olmsted County study, the prevalence of ascending aorta dilation (>40 mm) was 15%
and in the subset of patients with repeat measurements, the prevalence increased to 39% at
study completion. Dilation of the ascending aorta was an independent risk factor for ascend‐
ing aorta surgery. Although there are a number of risk factors associated with dilation of the
ascending aorta including increased systolic blood pressure, male sex, and significant valve
disease, the most important variable is likely age [50,63,64]. Aortic root size is shown to be re‐
lated to valve morphology and the presence of significant valve disease. In the Toronto series,
the prevalence of dissection was 0.1% per patient-year of follow-up, and in the Olmsted Coun‐
ty study, there were no cases of dissection. Despite the low rates of dissection, the increased‐
prevalence of BAV disease relative to Marfan syndrome make dissections due to BAV equal to
or more common than dissections due to Marfan syndrome [86]. Dissection in BAV, when it oc‐
curs, typically involves the ascending aorta, but involvement of the descending aorta has been
reported in older patients. Although dissection is more common in patients with dilated aor‐
tas, there are reports of dissection in normal-sized aortic roots and after valve replacement.
Risk factors for dissection have included aortic size, aortic stiffness, male sex, family history,
and the presence of other lesions such as coarctation of the aorta or Turner syndrome [50].
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3.4. Endocarditis
Endocarditis is more common in BAV. The estimated incidence is 0.16% per year in unoper‐
ated children and adolescents [87]. In adults the case series by Michelena give an incidence
of 2% per year [56].
Outcomes in BAV patients with infective endocarditis tend to be worse than in those with
normal valves. A recent study of 310 patients with infective endocarditis found that the 50
patients with BAV were younger at presentation and had a higher incidence of aortic peri‐
valvular abscess. In-hospital mortality and 5-year survival were also comparable to patients
with normal valves [22].
Most patients are unaware of their condition until the onset of infective endocarditis
Patients with BAV endocarditis are young, and there is strong male predominance. Staphy‐
lococci and viridans streptococci account for nearly three-quarters of the cases affecting
BAVs. Endocarditis can lead to severe acute aortic incompetence, heart failure and it is poor‐
ly tolerated [88].
Endocarditis risk was estimated to range between 2% or 0.3%/year. Because the risk of endo‐
carditis is felt to be low, the ACC/AHA practice guidelines no longer suggest bacterial endo‐
carditis prophylaxis in patients with straightforward BAV disease, except in patients with a
prior history ofendocarditis [50,89].
3.5. Coronary artery disorders
Some reports have also suggested that the involvement of coronary arteries, including con‐
genital coronary artery anomalies, coronary artery fistulas, spontaneous coronary artery dis‐
section, immediate bifurcation and a shorter length of the left main coronary artery [6,13].
The incidence of left dominance in BAVs has been found to be unusually high (24.4-56.8%),
compared with the incidence in tricuspid valves [9.5%]. Patients with BAVs have higher in‐
cidence of immediate bifurcation of the left main coronary artery, and higher incidence of
left main coronary length less than 10 mm. The mean length of the left main coronary artery
is significantly shorter in BAV patients [90].
Anomalous origins of the right 20,21 and left 22 coronary arteries, association with annu‐
loaortic ectasia, and anomalous origins of the left circumflex coronary artery 23 and single
left coronary artery,24 have been noted in patients with BAVs. Spontaneous coronary artery
dissection may occur in BAV patients [91]
There have also been some case reports describing patients with BAVdisease associated
with coronary heart disease [92] and even with acute myocardial infarction[10].
Also Recently studies[93]Yuan et al. suggested that the prevalence rate of angiographic cor‐
onary heart disease was higher among the patients with BAVdisease.
3.6. Congenıtal heart defects
Patent ductus arteriosus and ventricular septal defect are the most frequent congenital heart
defects associated with BAV. Patent ductus arteriosus is usually present in pediatric patients
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with BAV and may be associated with hand anomalies. BAV is reported to be present in up
to 30 % of adult patients with small ventricular septal defects. However, BAV may also be
associated with large ventricular septal defects and poor clinical outcome. There is signifi‐
cantly higher incidence of aortic arch obstruction (51.1%). The frequency of BAV in speci‐
mens with complete transposition of great arteries has been found to be 1% [13,50].
Hypoplastic left heart syndrome, complete atrioventricular canal defect, Ebstein’s anomaly,
partial or total anomalous pulmonary venous return, tetralogy of Fallot, double-outlet right
ventricle, septal left ventricular diverticulum,Williams syndrome,Down syndrome and an‐
nuloaortic ectasia are occasionally associated with BAV. Shone’s complex, which is defined
by four cardiovascular defects including supravalvular mitral membrane, valvular mitral
stenosis with a parachute mitral valve, subaortic stenosis and aortic coarctation, is a rare en‐
tity and forms another association in BAV cases [94].
It has been reported that BAV is presented in > 50 % of patients with coarctation of the aorta
[COA]. Patients with COA and BAV are reported to have more severe disease associated
with aortic stenosis, aortic regurgitation, and aortic aneurysm. The risk of dissection of the
aorta and death is greater when COA and BAV are comorbid.
Turner syndrome characterized by a defect in or the absence of one X chromosome. Except for
gonadal dysgenesis, cardiovascular defects are commonly present in this group of patients.
Clinical research on patients with Turner Syndrome reports that BAV is present in 30% of cas‐
es, that over 95% of BAV s result from fusion of the right and left coronary leaflets, and that
aortic ascending diameters are significantly greater in this group of patients [13].
3.7. Thromboembolism
Thrombus formation in a native BAV is a rare complicaton. Pathological studies have indi‐
cated that post-inflammatory changes ocur in the resected BAV, which is prone to develop
thrombosis on the valve surface or in the calcification area [95].
Microthrombus formation and valve thickening with incompetence could result in emboli‐
zation, and subsequent cerebrovascular events [96].
Embolization from calcific BAVs may lead to stroke and myocardial infarction. Conservative
management with anticoagulation, to treat associated post-stagnation thrombosis, or aortic
valve replacement as the treatment, is debatable [97].
4. Management
4.1. Medical
Medical therapies are to try and alleviate symptoms and slow progression. It is generally felt
that blood pressure should be aggressively controlled to try and slow the progression of
aortopathy [51].
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High blood pressure should be aggressively treated in patients with BAV disease. In Mar‐
fan-associated aortopathy, treatment with beta-blockers to slow the rate of progression is the
standard of care at many centers, although debate exists about their effectiveness [50,101].
The ACC/AHA guidelines for the management of adult congenital heart disease and guide‐
lines for the management of patients with valvular heart disease suggest that it is reasonable
to use beta-blockers in this population [Class IIa recommendation] [53]. There are emerging
data in animal models and in 1 small study in humans supporting the use of angiotensin II
receptor blockers to decreased aortic root dilation in Marfan syndrome [50]. Whether these
agents will have a role in BAV aortopathy has not yet been demonstrated. Also long-term
vasodilator therapy in BAV disease with aortic regurgitation is only recommended if there is
concomitant systemic hypertension [47]. The relationship between risk factors for athero‐
sclerosis and the development and progression of degenerative aortic valve disease has been
well studied [99]. However, the role of treatment with cholesterol-lowering agents is unre‐
solved. The use of lipid lowering agents specifically in young patients with BAV has not
been studied, and the current ACC/AHA guidelines for the management of patients with
valvular heart disease do not endorse the use of statins to slow the degenerative process in
this population [51]. Concomitant conditions and risk factors should be treated as in the nor‐
mal population.
4.2. Surgical
Indications for valve surgery in patients with BAV are similar to those with tricuspid aortic
valve disease or degenerative aortic valve disease [100].
The 2006 AHA/ACC guidelines also suggest concomitant replacement of the ascending aor‐
ta if it is greater than 45 mm in diameter [51]. Estimated 15-year freedom from complications
was 86% in patients with an aortic diameter less than 40 mm, dropping down to 81% in
those with diameter 40–44 and 43% in patients with a diameter 45 mm or greater.
When rheumatic disease is excluded, a significant portion of adults undergoing surgery for
aortic valve disease will have a congenitally malformed valve. During childhood, insertion
of a prosthetic valve is suboptimal because of the continuing growth of the child. Fortunate‐
ly, at this stage, the aortic valve is usually not calcified and valvuloplasty can successfully
disrupt the commissural fusion and relieve obstruction. Valvuloplasty is the interventional
strategy of choice in children and in some young adults with BAV and aortic stenosis.
Symptomatic aortic stenosis is an indication for intervention, similar to standard indications
for trileaflet valve disease. However, in the pediatric setting, indications include children
with peak-topeak gradients >50 mm Hg who develop symptom at rest or with exercise. An
additional indication includes asymptomatic children with peak-to-peak gradients >60 mm
Hg. In adulthood, aortic valve replacement is the most common intervention for either aort‐
ic valve stenosis or incompetence, and valvuloplasty is rarely performed [50,51,62].
BAV disease involves younger patients and involves both the valves and the ascendan aorta;
therefore, surgical decision making is more complicated. Approximately 30% of adults un‐
dergoing aortic valve replacement will also need aortic root surgery[63]. The guideline sug‐
gest that a cutoff of 5.0 cm be used for intervention or 4.5 cm if the surgery is otherwise
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being performed for valve indications. In addition, suggest that changes in root size more
than 0.5 cm/year are an indication for root replacement [53].
Recently published Guidelines [53] for the diagnosis and management of patients with
thoracic aortic disease recommendations for BAV are summarized below:
CLASS I
1. First-degree relatives of patients with a BAV, premature onset of thoracic aortic disease
with minimal risk factors, and/or a familial form of thoracic aortic aneurysm and dissec‐
tion should be evaluated for the presence of a BAV and asymptomatic thoracic aortic
disease. (Level of Evidence: C)
2. All patients with a BAV should have both the aortic root and ascending thoracic aorta
evaluated for evidence of aortic dilatation (Level of Evidence: B)
3. Should undergo elective operation at smaller diameters (4.0 to 5.0 cm)to avoid acute
dissection or rupture. ()Level of Evidence: C)
4. Patients with a growth rate of more than 0.5 cm/year in an aorta that is less than 5.5 cm
in diameter should be considered for operation. (Level of Evidence: C)
5. Patients undergoing aortic valve repair or replacement and who have an ascending aor‐
ta or aortic root of greater than 4.5 cm should be considered for concomitant repair of
the aortic root or replacement of the ascending aorta. (Level of Evidence: C)
6. Elective aortic replacement is reasonable for patients with BAV when the ratio of maxi‐
mal ascending or aortic root area (πr2) in cm2 divided by the patient’s height in meters
exceeds 10 (CLASS IIa, Level of Evidence: C).
In regard to valve surgery, there is controversy regarding the use of the Ross procedure and
the use of valve repairs in this population. Abnormalities of the media are seen in both the
aorta and the pulmonary artery in BAV disease. Intrinsic abnormalities in the wall of the
pulmonary artery [neoaorta] may contribute to progressive neoaortic root dilation and/or
aortic regurgitation when the pulmonary root is placed in the systemic position [101].
When to surgically treat asymptomatic patients with BAV remains controversial. The risk of
sudden death in asymptomatic adult patients with severe aortic stenosis is reported to be
less than 1% per year, however, current practice guidelines recommended aortic valve re‐
placement in patients with reduced left ventricular systolic function (EF< 50%) without oth‐
er explanation even when they are asymptomatic [51].
For high-risk patients to undergo conventional novel methods including aortic balloon valvu‐
lotomy or transfemoral valve implantation may be helpful. A patient considered inoperable
should be treated orally with angiotensin converting enzyme (ACE) inhibitors, diuretics, and
digitalis. In patients with depressed LV associated with pulmonary congestion and atrial fibril‐
lation, diuretics and digitalis may be used with the understanding that in some cases intensive
hemodynamic monitoring is needed. Patients with aortic root dilatation > 4.0cm who are not
candidate for surgical treatment should be given β-adrenergic blocking agents [51].
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4.3. Pregnancy
During pregnancy there are changes in hemodynamics as well as changes in the aortic me‐
dia, and therefore, women with BAV and significant aortic stenosis and/or dilated aortic
roots are at risk for complications during pregnancy.
In rare instances, women will develop progressive symptoms during pregnancy and require
either valvuloplasty or valve surgery. Both interventions can be performed during pregnan‐
cy, but are associated with both maternal and fetal risks and should be performed only
when necessary.
Although pregnancy can be successfully completed in most instances, aortic surgery may be
required early after pregnancy in some women with severe aortic stenosis. Pregnancy itself
seems to accelerate the need for surgery postpartum in women with moderate or severe
aortic stenosis, perhaps by affecting the ability of the left ventricle to adapt to the fixed out‐
flow obstruction. It is therefore important that women be counseled about both the risk of
pregnancy and the potential for late complications [102,103].
Additionally, guidelines suggest that women with BAV and significant aortopathy (ascend‐
ing aorta diameter >4.5 cm)“should be counseled against the high risk of pregnancy” [43].
4.4. Exercise
There are little data available to support recommendations regarding exercise in subjects
with BAV. In children with congenital severe aortic stenosis, for instance, sudden death can
occur during exercise [121]. The Task Force on Exercise in Patients with Heart Disease rec‐
ommends that athletes with severe aortic stenosis or severe aortic incompetence with left
ventricular dilation [left ventricular dimensions >65 mm] should not participate in competi‐
tive athletics. Athletes with or without aortic valve disease who have dilated aortic roots
(>45 mm) are advised to only participate in low-intensity competitive sports. No restrictions
exist for those with BAV with no significant valve dysfunction or aortic root/ascending aorta
dilation(>40 mm) [50,104,105].
5. Conclusions
Consequently aortic stenosis and regurgitation, infective endocarditis and aortic dissection
are the most common complications of BAV additionaly this process continues after valve
replacement. The person with BAV requires continuous surveillance to treat associated le‐
sions and prevent complications. Arterial hypertension should be meticulously controlled.
Smoking should be discouraged and control of hypercholesterolaemia considered, in view
of the impact of these factors on the development of aortic stenosis. Aortic root dilatation is
common in BAV, even when the valve is haemodynamically normal, and consequently aort‐
ic dissection usually occurs in previously asymptomatic patients. Beta-blockers and statins
are the possibilities for medical treatment, and aortic valve repair/replacement and ascend‐
ing aorta replacement are indicated for patients with a severely diseased aortic valve and
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aorta. All patients should therefore be regularly reviewed to identify progressive root dilata‐
tion [6,94].
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